Skip to main content

Table 1 Clinical PARP inhibitors

From: Advances and perspectives of PARP inhibitors

PARP inhibitor

Olaparib

Rucaparib

Niraparib

Talazoparib

Veliparib

Approvals

Ovarian cancer

Breast cancer

Ovarian cancer

Ovarian cancer

Ovarian cancer

Not approved

PARP trapping potency

Middle

Middle

Middle

High

Low

Recommended dose

300 mg BID

600 mg BID

300 mg BID

1 mg QD

600 mg BID

The most common adverse reactions (in at least 20% patients)

Anemia, nausea, fatigue, vomiting, nasopharyngitis, diarrhea, arthralgia/myalgia, dysgeusia, headache, dyspepsia, decreased appetite, constipation, and stomatitis

Nausea, fatigue, vomiting, anemia, abdominal pain, dysgeusia, constipation, decreased appetite, diarrhea, thrombocytopenia, and dyspnea

Nausea, thrombocytopenia, fatigue, anemia, constipation, vomiting, neutropenia, headache, decreased appetite, insomnia, abdominal pain

Fatigue, anemia, nausea, neutropenia, headache, thrombocytopenia, vomiting, alopecia, diarrhea, decreased appetite

Nausea, fatigue

  1. Data of Olaparib, Rucaparib, Niraparib, and Talazoparib are obtained from https://www.fda.gov/
  2. Data of Veliparib is obtained from NCT01149083